about
Maternal occupational exposure to polycyclic aromatic hydrocarbons and small for gestational age offspringMaternal occupational exposure to polycyclic aromatic hydrocarbons and congenital heart defects among offspring in the National Birth Defects Prevention StudyAssociation between maternal occupational exposure to organic solvents and congenital heart defects, National Birth Defects Prevention Study, 1997-2002Projecting Month of Birth for At-Risk Infants after Zika Virus Disease OutbreaksEstimating the Number of Pregnant Women Infected With Zika Virus and Expected Infants With Microcephaly Following the Zika Virus Outbreak in Puerto Rico, 2016The National Birth Defects Prevention Study: A review of the methodsAntihistamines and birth defects: a systematic review of the literature.Baseline Prevalence of Birth Defects Associated with Congenital Zika Virus Infection — Massachusetts, North Carolina, and Atlanta, Georgia, 2013–2014Assessment of YouTube videos as a source of information on medication use in pregnancyUsing an existing birth defects surveillance program to enhance surveillance data on stillbirths.Population-based birth defects data in the United States, 2008 to 2012: Presentation of state-specific data and descriptive brief on variability of prevalence.Using insurance claims data to identify and estimate critical periods in pregnancy: An application to antidepressants.Reporting birth defects surveillance data 1968-2003.Perfluorooctanoate exposure and major birth defects.Maternal exposure to criteria air pollutants and congenital heart defects in offspring: results from the national birth defects prevention study.Diabetes mellitus and birth defects.Racial/ethnic variations in the prevalence of selected major birth defects, metropolitan Atlanta, 1994-2005.Maternal intake of vitamin E and birth defects, national birth defects prevention study, 1997 to 2005.Late detection of critical congenital heart disease among US infants: estimation of the potential impact of proposed universal screening using pulse oximetryEstimated number of infants detected and missed by critical congenital heart defect screening.Is maternal parity an independent risk factor for birth defects?Prenatal diagnosis of nonsyndromic congenital heart defectsMethods for surveillance of fetal alcohol syndrome: The Fetal Alcohol Syndrome Surveillance Network II (FASSNetII) - Arizona, Colorado, New York, 2009 - 2014Estimate of the potential impact of folic acid fortification of corn masa flour on the prevention of neural tube defectsPrevalence of prescription medication use among non-pregnant women of childbearing age and pregnant women in the United States: NHANES, 1999-2006.The need for safer medication use in pregnancy.Trends in Gestational Diabetes Among Hospital Deliveries in 19 U.S. States, 2000-2010.Evaluation of an active surveillance system for stillbirths in metropolitan Atlanta.Racial/ethnic differences in infant mortality attributable to birth defects by gestational age.Use of topiramate in pregnancy and risk of oral clefts.Racial/ethnic differences in survival of United States children with birth defects: a population-based study.Use of antihistamine medications during early pregnancy and isolated major malformations.Mortality resulting from congenital heart disease among children and adults in the United States, 1999 to 2006Lack of periconceptional vitamins or supplements that contain folic acid and diabetes mellitus-associated birth defects.Congenital Heart Defects in the United States: Estimating the Magnitude of the Affected Population in 2010.Limitations, depressive symptoms, and quality of life among a population-based sample of young adults with congenital heart defects.Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008.Proportion of selected congenital heart defects attributable to recognized risk factors.Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk.Zika Virus Disease in Children in Colombia, August 2015 to May 2016.
P50
Q23919439-6C3F1578-D1D1-409C-8441-055DC570C56DQ23919548-D878D56D-1ADE-49BC-BE15-A172C6A664EDQ23922098-44591C75-5517-486D-830D-0569F6EC72B1Q24261128-CC6D56F4-523C-4182-840C-6EFCE1891F02Q26406299-050E25D2-6D50-44B7-B812-A315096A653AQ27339504-AFE84CD1-1B06-4D22-B845-4DA22B3906C2Q27348110-BF347CD5-2C54-47CE-A02F-58B9D04D3306Q28956693-5B222B3F-1540-4F75-9D68-59C65C248450Q30697219-E903539A-F3AC-48BA-8E42-121C9B3A3135Q30828672-FC92D850-D308-4BF1-B25E-AD65E2BF34EBQ31028648-DB980AF3-F57E-451D-9B89-E432614113ADQ31145022-C68B95B7-C398-47F7-BDEF-7E9CD1FA4250Q33271967-B0C397FB-162E-492C-A7CC-FE896A1FABBDQ33984406-E54CE25A-DFCB-4F3B-8749-F17D3D833977Q34007578-0E3D9D52-8F58-4449-9041-8731A47A6091Q34803469-8CBAAD5F-9B90-4D2C-9F8F-588B59E45799Q35603340-3733DA3F-EA79-41D1-9A86-6B8D8ADEDD25Q35734647-D462C33C-5A1C-4B1A-8945-9314BA128EEAQ35751069-96674FA2-90D5-4580-AA0F-FB21E66B8000Q35751376-74E1932F-FF5C-48CF-94B9-05781A71F035Q35764608-4A0D90DC-CBE7-45E7-A579-C48D4BF99F1EQ35787436-98F35DA2-E770-46D8-A9EF-D8A8E0C48F60Q35794821-D02DB6F5-E083-4942-9F05-6EFDB94ACE05Q35891718-60733773-267A-4E83-AFA5-8372C0099A72Q35891733-C0D2EA46-758D-4DDC-A172-A80DDF5BDBA2Q35926283-7D7BB8E8-44EC-44B9-925D-80A16F507B02Q35939737-4DB77EAD-5062-4EAA-87DD-261E3C6E7F23Q35939902-353537A1-F60E-4BD2-8A00-FCC5D38087D8Q36161039-34DAA1D0-2CDE-49FB-89BA-BC0A841F51CDQ36356810-0138B0B9-DF30-44DA-BD8D-85DE93B571DEQ36417617-BA04F513-A1D2-4767-B5BD-B5D709EE3DB8Q36747269-93AC4134-EE28-435A-9D05-4F0748D37F76Q37013505-3A708CD3-DE98-4663-8F4E-9653DAD8795EQ37025015-2FF95717-B1E1-42F3-9893-99176A399251Q37088620-649E494E-F13F-4F0B-BF44-1C6556F278BAQ37210291-0F38718E-AA62-4461-994E-2C3752F1842CQ37222764-2F45E61A-13CB-4DF0-A2F6-71318B735459Q37560116-48687738-ADB7-4CD7-90C6-2C6312BACC93Q37718640-68050E77-064B-4A6C-A2E2-D0AF7171C935Q38156758-20F6BCEC-2369-4F91-B3FA-5DCC2C602413
P50
name
Suzanne M Gilboa
@ast
Suzanne M Gilboa
@en
Suzanne M Gilboa
@nl
type
label
Suzanne M Gilboa
@ast
Suzanne M Gilboa
@en
Suzanne M Gilboa
@nl
prefLabel
Suzanne M Gilboa
@ast
Suzanne M Gilboa
@en
Suzanne M Gilboa
@nl